Pasadena Showcase House for the Arts Debuts its Newest Collection of Gems for 2015 – 2016

first_img Your email address will not be published. Required fields are marked * Top of the News Community News L-R: Patricia Kent of Quartz Hill, Melinda Marston of San Marino, Tracie Thompson of Lakewood.Pasadena Showcase House for the Arts (PSHA) introduced their new Provisional Members at the first General Meeting of the year held at the Walt Disney Concert Hall. Collectively known as The Gems, the four women, led by Provisional Chair Barbara Lake, are eager to take on the hard work, commitment, and camaraderie that being a member of PSHA brings.“The group is named The Gems because,” as Barbara relates, “each gemstone is unique with a special color, birthplace, and story.”The new Provisional Members are unique just like their gemstone counterparts. Patricia Kent (Emerald) of Quartz Hill owns a construction company; Melinda Marston (Ruby) of San Marino is a residential real estate broker; Catherine Smith (Sapphire) of La Cañada-Flintridge is a former lawyer and current stay-at-home mom; and Tracie Thompson (Pearl) of Lakewood is Assistant Vice President and Risk Officer of a financial services company in Beverly Hills.“The backbone of our organization is our dedicated volunteers,” stated PSHA President Gretchen McNally. “We are indeed fortunate to have again a group of Provisionals ready to take on the challenge of Showcase.”To familiarize the Provision group with all the facets of PSHA, Barbara has introduced a mentoring program that pairs each Provisional Member with a current Active Member. Stepping up to offer guidance this year are Active Members Debra Qurtman, Cora Handayan, Elsa Balding, and Marsha Seyffert. These mentors will help integrate the new members into PSHA’s wide variety of work, including its three key music programs, as well as the Pasadena Showcase House of Design that takes place April 17 to May 15, 2016.About Pasadena Showcase House for the ArtsAn all-volunteer organization, PSHA is a non-profit California Corporation whose members donate their time and talents to produce the annual Pasadena Showcase House of Design, one of the oldest, largest and most successful house and garden tours in the nation. PSHA celebrated the milestone of its fiftieth Showcase House in 2014. Founded in 1948, the organization has donated nearly $20 million to provide music programs in the community. Examples include the underwriting of concerts, choral productions, musical theater, opera, jazz quartets, marching bands, and orchestras at local schools, senior centers, and many other non-profit organizations. Additionally, a staple part of PSHA’s program is music therapy for at-risk children, scholarships for young musicians, and music education at a variety of levels. This is in addition to their longstanding support of the Los Angeles Philharmonic Association. They also produce three highly regarded annual music programs: Music Mobile™, Instrumental Competition and Youth Concert. An essential part of PSHA’s mission is to nurture the study and appreciation of music and to ensure that music is available to a broad range of audiences. For over 65 years, PSHA has funded and produced programs that have enriched the lives of countless people and brought a lasting legacy to the community. Subscribe Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. First Heatwave Expected Next Week Name (required)  Mail (required) (not be published)  Website  Make a comment Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday HerbeautyIs It Bad To Give Your Boyfriend An Ultimatum?HerbeautyHerbeautyHerbeautyFinding The Right Type Of Workout For You According AstrologyHerbeautyHerbeautyHerbeautyInstall These Measures To Keep Your Household Safe From Covid19HerbeautyHerbeautyHerbeauty15 Countries Where Men Have Difficulties Finding A WifeHerbeautyHerbeautyHerbeautyThese Lipsticks Are Designed To Make Your Teeth Appear Whiter!HerbeautyHerbeautyHerbeautyStop Eating Read Meat (Before It’s Too Late)HerbeautyHerbeautycenter_img Business News Design Pasadena Showcase House for the Arts Debuts its Newest Collection of Gems for 2015 – 2016 From STAFF REPORTS Published on Tuesday, November 10, 2015 | 11:17 am 10 recommended0 commentsShareShareTweetSharePin it Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy Community News More Cool Stuff faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Virtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyCitizen Service CenterPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadenalast_img read more

Guided Therapeutics Raises US $1.1 Million in New Preferred Stock Offering

first_img Facebook Twitter Pinterest Facebook TAGS  Guided Therapeutics Raises US $1.1 Million in New Preferred Stock Offering Previous articleBasware Named a Leader in IDC MarketScape Procure-to-Pay AssessmentNext articlenVent Electric plc to Participate in the Barclays Industrial Select Conference Digital AIM Web Support By Digital AIM Web Support – February 16, 2021 center_img Twitter Local NewsBusiness WhatsApp WhatsApp Pinterest PEACHTREE CORNERS, Ga.–(BUSINESS WIRE)–Feb 16, 2021– Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has thus far raised a total of US $1.1 million under the terms of a Series F Preferred Stock Offering. The private placement offering targeted at least U.S. $1 million and the financing can continue to raise additional funds until closing this tranche, forecast for later this month. As specified by terms of the investment, proceeds from the Series F Financing were to make the final payment of $750,000 due to GPB Holdings, LLC and to conduct the Company sponsored U.S. FDA clinical trial this year for its flagship product the LuViva Advanced Cervical Scan. The final payment was made to GPB on January 9, 2021, which satisfied the security lien on the Company’s assets and removed over $5 million in liabilities from the Company’s balance sheet. Completing enrollment in the FDA study this year is the Company’s most critical milestone and funds from the Series F Financing, cash on hand and revenues from existing purchase orders will be used to complete enrollment in the FDA study. The Series F Preferred shares are convertible at a fixed price of 25 cents per share, carry a 6% annual dividend and could potentially include an additional dividend of 15% after twelve months if the Company is unable to uplist to a national exchange or complete its FDA study. The dividends can be paid in cash or common shares at the option of the Company. Aspen Capital acted as Financial Advisor to the Company with respect to the private placement. “In 2020 we identified making the final payment to GPB and completing the FDA study as necessary to the existence and significant growth of our Company. We are extremely pleased that we have been able to raise sufficient funds for these purposes, pending the final closing of the Series F financing,” said Gene Cartwright, Guided Therapeutics CEO. “Since we have reached agreement with the FDA regarding the study protocol, we are now engaged with clinical study centers that will enroll their patients in our study and are actively building clinical trial devices. It is now full speed ahead with the study.” About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com. The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and “Early detection, better outcomes” are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and subsequent filings. View source version on businesswire.com:https://www.businesswire.com/news/home/20210216005242/en/ CONTACT: Mark Faupel Guided Therapeutics 770-242-8723 ext. 303 KEYWORD: UNITED STATES NORTH AMERICA GEORGIA INDUSTRY KEYWORD: RESEARCH MEDICAL DEVICES FDA BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE SOURCE: Guided Therapeutics Copyright Business Wire 2021. PUB: 02/16/2021 09:05 AM/DISC: 02/16/2021 09:05 AM http://www.businesswire.com/news/home/20210216005242/enlast_img read more

Chronic illness is the ‘biggest killer’, says WHO

first_img Tweet The report said smoking was one of the leading causes of noncommunicable diseaseChronic illnesses such as heart disease, cancer and diabetes are the leading cause of death globally, according to the World Health Organization.The Global Status report said so-called noncommunicable diseases accounted for more than 36m deaths in 2008.It showed 80% of the deaths were in low and middle income countries.It said they posed a greater threat than infectious diseases such as malaria, HIV and tuberculosis.Dr Margaret Chan, WHO Director General, said: “The rise of chronic noncommunicable diseases presents an enormous challenge.“For some countries, it is no exaggeration to describe the situation as an impending disaster; a disaster for health, for society, and most of all for national economies.Chronic noncommunicable diseases deliver a two-punch blow to development. They cause billions of dollars in losses of national income, and they push millions of people below the poverty line, each and every year.”The WHO said many of the deaths could be prevented by introducing policies such as promoting healthier diets and stronger smoking legislation.BBC News Sharing is caring! Share HealthLifestyle Chronic illness is the ‘biggest killer’, says WHO by: – April 27, 2011center_img 25 Views   no discussions Share Sharelast_img read more